Joe-Elie Salem1,2,3, M Benjamin Shoemaker1, Lisa Bastarache4, Christian M Shaffer3, Andrew M Glazer3, Brett Kroncke3, Quinn S Wells1, Mingjian Shi4, Peter Straub1, Gail P Jarvik5,6, Eric B Larson5,7, Digna R Velez Edwards8,9, Todd L Edwards4, Lea K Davis1, Hakon Hakonarson10, Chunhua Weng11, David Fasel11, Bjorn C Knollmann3, Thomas J Wang1, Joshua C Denny4, Patrick T Ellinor12,13, Dan M Roden1,3,4, Jonathan D Mosley1,4. 1. Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee. 2. Sorbonne Université, Institut National de la Santé et de la Recherche Médicale (INSERM) CIC Paris-Est, AP-HP, Institute of Cardio metabolism and Nutrition (ICAN), Pitié-Salpêtrière Hospital, Department of Pharmacology, Paris, France. 3. Department of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee. 4. Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee. 5. Department of Medicine (Medical Genetics), University of Washington, Seattle. 6. Department Genome Sciences, University of Washington, Seattle. 7. Kaiser Permanente Washington Health Research Institute, Seattle. 8. Department of Obstetrics and Gynecology, Vanderbilt University Medical Center, Nashville, Tennessee. 9. Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee. 10. Divisions of Human Genetics and Pulmonary Medicine, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. 11. Department of Biomedical Informatics, Columbia University, New York. 12. Cardiovascular Research Center, Massachusetts General Hospital, Boston. 13. The Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
Abstract
Importance: Thyroid hormone levels are tightly regulated through feedback inhibition by thyrotropin, produced by the pituitary gland. Hyperthyroidism is overwhelmingly due to thyroid disorders and is well recognized to contribute to a wide spectrum of cardiovascular morbidity, particularly the increasingly common arrhythmia atrial fibrillation (AF). Objective: To determine the association between genetically determined thyrotropin levels and AF. Design, Setting, and Participants: This phenome-wide association study scanned 1318 phenotypes associated with a polygenic predictor of thyrotropin levels identified by a previously published genome-wide association study that included participants of European ancestry. North American individuals of European ancestry with longitudinal electronic health records were analyzed from May 2008 to November 2016. Analysis began March 2018. Main Outcomes and Measures: Clinical diagnoses associated with a polygenic predictor of thyrotropin levels. Exposures: Genetically determined thyrotropin levels. Results: Of 37 154 individuals, 19 330 (52%) were men. The thyrotropin polygenic predictor was positively associated with hypothyroidism (odds ratio [OR], 1.10; 95% CI, 1.07-1.14; P = 5 × 10-11) and inversely associated with diagnoses related to hyperthyroidism (OR, 0.64; 95% CI, 0.54-0.74; P = 2 × 10-8 for toxic multinodular goiter). Among nonthyroid associations, the top association was AF/flutter (OR, 0.93; 95% CI, 0.9-0.95; P = 9 × 10-7). When the analyses were repeated excluding 9801 individuals with any diagnoses of a thyroid-related disease, the AF association persisted (OR, 0.91; 95% CI, 0.88-0.95; P = 2.9 × 10-6). To replicate this association, we conducted an inverse-variance weighted average meta-analysis using AF single-nucleotide variant weights from a genome-wide association study of 17 931 AF cases and 115 142 controls. As in the discovery analyses, each SD increase in predicted thyrotropin was associated with a decreased risk of AF (OR, 0.86; 95% CI, 0.79-0.93; P = 4.7 × 10-4). In a set of AF cases (n = 745) and controls (n = 1680) older than 55 years, directly measured thyrotropin levels that fell within the normal range were inversely associated with AF risk (OR, 0.91; 95% CI, 0.83-0.99; P = .04). Conclusions and Relevance: This study suggests a role for genetically determined variation in thyroid function within a physiologically accepted normal range as a risk factor for AF. The clinical decision to treat subclinical thyroid disease should incorporate the risk for AF as antithyroid medications to treat hyperthyroidism may reduce AF risk and thyroid hormone replacement for hypothyroidism may increase AF risk.
Importance: Thyroid hormone levels are tightly regulated through feedback inhibition by thyrotropin, produced by the pituitary gland. Hyperthyroidism is overwhelmingly due to thyroid disorders and is well recognized to contribute to a wide spectrum of cardiovascular morbidity, particularly the increasingly common arrhythmia atrial fibrillation (AF). Objective: To determine the association between genetically determined thyrotropin levels and AF. Design, Setting, and Participants: This phenome-wide association study scanned 1318 phenotypes associated with a polygenic predictor of thyrotropin levels identified by a previously published genome-wide association study that included participants of European ancestry. North American individuals of European ancestry with longitudinal electronic health records were analyzed from May 2008 to November 2016. Analysis began March 2018. Main Outcomes and Measures: Clinical diagnoses associated with a polygenic predictor of thyrotropin levels. Exposures: Genetically determined thyrotropin levels. Results: Of 37 154 individuals, 19 330 (52%) were men. The thyrotropin polygenic predictor was positively associated with hypothyroidism (odds ratio [OR], 1.10; 95% CI, 1.07-1.14; P = 5 × 10-11) and inversely associated with diagnoses related to hyperthyroidism (OR, 0.64; 95% CI, 0.54-0.74; P = 2 × 10-8 for toxic multinodular goiter). Among nonthyroid associations, the top association was AF/flutter (OR, 0.93; 95% CI, 0.9-0.95; P = 9 × 10-7). When the analyses were repeated excluding 9801 individuals with any diagnoses of a thyroid-related disease, the AF association persisted (OR, 0.91; 95% CI, 0.88-0.95; P = 2.9 × 10-6). To replicate this association, we conducted an inverse-variance weighted average meta-analysis using AF single-nucleotide variant weights from a genome-wide association study of 17 931 AF cases and 115 142 controls. As in the discovery analyses, each SD increase in predicted thyrotropin was associated with a decreased risk of AF (OR, 0.86; 95% CI, 0.79-0.93; P = 4.7 × 10-4). In a set of AF cases (n = 745) and controls (n = 1680) older than 55 years, directly measured thyrotropin levels that fell within the normal range were inversely associated with AF risk (OR, 0.91; 95% CI, 0.83-0.99; P = .04). Conclusions and Relevance: This study suggests a role for genetically determined variation in thyroid function within a physiologically accepted normal range as a risk factor for AF. The clinical decision to treat subclinical thyroid disease should incorporate the risk for AF as antithyroid medications to treat hyperthyroidism may reduce AF risk and thyroid hormone replacement for hypothyroidism may increase AF risk.
Authors: Anne R Cappola; Linda P Fried; Alice M Arnold; Mark D Danese; Lewis H Kuller; Gregory L Burke; Russell P Tracy; Paul W Ladenson Journal: JAMA Date: 2006-03-01 Impact factor: 56.272
Authors: Joshua C Denny; Marylyn D Ritchie; Melissa A Basford; Jill M Pulley; Lisa Bastarache; Kristin Brown-Gentry; Deede Wang; Dan R Masys; Dan M Roden; Dana C Crawford Journal: Bioinformatics Date: 2010-03-24 Impact factor: 6.937
Authors: C T Sawin; A Geller; P A Wolf; A J Belanger; E Baker; P Bacharach; P W Wilson; E J Benjamin; R B D'Agostino Journal: N Engl J Med Date: 1994-11-10 Impact factor: 91.245
Authors: H Alonso; J Fernández-Ruocco; M Gallego; L L Malagueta-Vieira; A Rodríguez-de-Yurre; E Medei; O Casis Journal: J Mol Cell Cardiol Date: 2015-10-20 Impact factor: 5.000
Authors: Jonathan D Mosley; Sara L van Driest; Quinn S Wells; Christian M Shaffer; Todd L Edwards; Lisa Bastarache; Catherine A McCarty; Will Thompson; Christopher G Chute; Gail P Jarvik; David R Crosslin; Eric B Larson; Iftikhar J Kullo; Jennifer A Pacheco; Peggy L Peissig; Murray H Brilliant; James G Linneman; Josh C Denny; Dan M Roden Journal: Circ Cardiovasc Genet Date: 2016-10-25
Authors: Mingjian Shi; Ali M Manouchehri; Christian M Shaffer; Nataraja Sarma Vaitinadin; Jacklyn N Hellwege; Joe-Elie Salem; Lea K Davis; Jill H Simmons; Dan M Roden; M Benjamin Shoemaker; Jane F Ferguson; Jonathan D Mosley Journal: J Clin Endocrinol Metab Date: 2021-06-16 Impact factor: 5.958
Authors: Enrique Soto-Pedre; Moneeza K Siddiqui; Ify Mordi; Cyrielle Maroteau; Jimena Soto-Hernaez; Colin N A Palmer; Ewan R Pearson; Graham P Leese Journal: Eur Thyroid J Date: 2021-08-19
Authors: Timothy E Thayer; Rebecca T Levinson; Shi Huang; Tufik Assad; Eric Farber-Eger; Quinn S Wells; Jonathan D Mosley; Evan L Brittain Journal: Chest Date: 2020-07-24 Impact factor: 9.410
Authors: Julieta Lazarte; Jacqueline S Dron; Adam D McIntyre; Allan C Skanes; Lorne J Gula; Anthony S Tang; Rafik Tadros; Zachary W Laksman; Robert A Hegele; Jason D Roberts Journal: CJC Open Date: 2021-02-06
Authors: Enrique Soto-Pedre; Moneeza K Siddiqui; Cyrielle Maroteau; Adem Y Dawed; Alex S Doney; Colin N A Palmer; Ewan R Pearson; Graham P Leese Journal: Front Genet Date: 2021-06-23 Impact factor: 4.599